Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. reports developments tied to its autologous blood-based stem cell therapy platform, including VesCell™ (ACP-01), a patient-derived angiogenic cell therapy associated with ischemic and vascular-related conditions. Company news commonly covers clinical-study history, published results, FDA interactions, physician education, and commercialization activity in markets such as Florida, Canada, and The Bahamas.
Recurring updates also include private placements and other capital actions, leadership and scientific-advisory appointments, shareholder and governance matters, and regulatory planning for ACP-01 across indications including peripheral arterial disease, chronic limb threatening ischemia, angina, cardiomyopathies, congestive heart failure, and vascular dementia.
Hemostemix (OTCQB: HMTXF), a leading autologous stem cell therapy company, has announced a non-brokered private placement of $280,594 at $0.125 per share. The company will issue 2,244,752 shares, subject to TSX Venture Exchange approval.
The company's flagship product, VesCell™ (ACP-01), treats various conditions including peripheral arterial disease, chronic limb threatening ischemia, and various cardiac conditions in Florida under SB 1768. The proceeds will support general working capital, operational expenses, and business development activities.
Hemostemix (OTCQB: HMTXF) has announced the launch of its upgraded HubSpot-powered corporate websites, marking a significant advancement in its digital marketing capabilities. The company, which offers VesCell™ (ACP-01) stem cell therapy for various conditions including peripheral arterial disease and heart conditions, has transformed its static websites into an integrated marketing and CRM sales platform.
The new platform features AI-driven patient engagement, HIPAA-compliant portals, and automated administrative workflows. Key improvements include streamlined lead generation, efficient patient intake, and targeted clinical partner outreach in Florida, where the therapy is available under SB 1768 for patients with life-threatening conditions who have exhausted standard treatment options.
The company expects to achieve 20% administrative cost savings and improved patient access through multilingual support and AI-powered capabilities. The platform will support Hemostemix's global expansion plans while maintaining regulatory compliance.
Hemostemix (OTCQB: HMTXF) has launched VesCell.Health, an educational website in Florida to support the rollout of its VesCell™ autologous stem cell therapy. The launch follows Florida's SB 1768 legislation, which now allows the use of VesCell™ for patients with life-threatening conditions who have exhausted standard treatment options.
The website serves as an educational platform explaining the therapy's benefits and includes 11 peer-reviewed publications documenting VesCell's safety and efficacy across seven clinical trials. The therapy targets multiple conditions including peripheral arterial disease, chronic limb threatening ischemia, angina, and various forms of cardiomyopathy.
Hemostemix (OTCQB: HMTXF) highlighted a remarkable patient success story of Howie Lindeman, who has gained over 17 years of life following a VesCell™ (ACP-01) treatment in 2008. Howie, a six-time Grammy Award-winning producer, received the autologous stem cell therapy for ischemic cardiomyopathy, resulting in his ejection fraction nearly doubling from the low 20% range to the 40% range.
The company's VesCell™ therapy, now authorized under Florida's SB 1768 for patients with life-threatening conditions, has treated 498 patients across seven clinical studies, with results documented in 11 peer-reviewed publications. Studies have shown up to a 47.1% increase in ejection fraction in dilated cardiomyopathy patients.
Hemostemix (OTCQB: HMTXF) has partnered with MedLoanFinancing to provide financing options for its VesCell™ (ACP-01) stem cell therapy treatments in Florida. The financing allows patients to access up to $50,000 in credit through monthly payment plans, making the treatment more accessible under Florida's SB 1768 law.
The company is presenting significant clinical trial results to medical facilities in Naples and Boca Raton. The trials showed that ulcer size in treated patients decreased from 1.46 cm² to 0.48 mm² within 3 months (p = 0.01), while the placebo group showed no significant improvement (p 0.54).
Hemostemix (OTCQB: HMTXF) has launched its face-to-face sales program in Florida for its VesCell™ (ACP-01) autologous stem cell therapy. The initiative focuses on Miami, Naples, and Tampa, leveraging Florida's SB 1768 law that allows advanced cell therapies for patients with life-threatening conditions who have exhausted standard treatments.
The company has treated 498 patients across seven clinical studies involving 318 subjects, resulting in 11 peer-reviewed publications. Clinical results show significant improvements in treating conditions like peripheral arterial disease, with ulcer size reduction from 1.46 cm² to 0.48 mm² in treated groups. The therapy has also demonstrated positive outcomes in treating chronic stable angina and improving cardiac function.
Hemostemix (OTCQB: HMTXF) has announced an enhanced investor awareness and social media strategy for its autologous stem cell therapy platform VesCell™. The company has reported $1,143,983 in Therapy Convertible Debenture sales year-to-date and is expanding its presence in Florida.
The company's treatment platform has demonstrated significant clinical results, including up to 47.1% increase in ejection fraction in cardiomyopathy patients and a 99% reduction in ulcerating wounds in Phase II CLTI trials. With 498 treatments completed and 11 peer-reviewed publications, Hemostemix is leveraging multiple social media platforms to reach both investors and potential patients suffering from various cardiovascular conditions.
Hemostemix (OTCQB: HMTXF), a leading autologous stem cell therapy company, has announced its AI strategy implementation plan through an upcoming webinar on August 21, 2025. The company's Chief Commercialization Officer, Croom Lawrence, will present their comprehensive approach to integrating AI across patient engagement, clinical research, and corporate operations.
The strategy encompasses three main areas: Patient Care Innovations including HIPAA-compliant precision medicine diagnostics and cognitive decline screening; Clinical & Scientific Advancement featuring AI-powered research and predictive analytics; and Operational Efficiency with automated workflows projected to reduce overhead by up to 20%.
Hemostemix (OTCQB: HMTXF) has announced a significant expansion of its marketing team to drive sales of its VesCell™ (ACP-01) therapy in Florida. The company has appointed three key executives: Croom Lawrence as Chief Commercial Officer, bringing 25+ years of biotech launch experience, Sana Farooqui as Fractional Chief Marketing Officer, and Bob Branch as Fractional VP of Digital Marketing & Media.
Under Florida's Right-to-Try statute, VesCell™ can now be offered to qualifying patients for treating conditions including PAD, CLTI, angina, and various cardiomyopathies. The therapy has shown promising results in multiple clinical trials, demonstrating improved circulation, reduced amputation needs, and enhanced cardiac function.
Hemostemix (OTCQB: HMTXF) has announced a new partnership with Empire Market Ventures (EMV), a New York City-based consulting firm specializing in investor market awareness and strategic communications. EMV will provide market awareness services to enhance Hemostemix's visibility in the capital markets.
The partnership aims to leverage EMV's expertise in digital media and market intelligence to develop comprehensive investor engagement strategies. EMV will operate independently and at arm's length from Hemostemix to ensure unbiased guidance and regulatory compliance.